Category: Publications
Search News
AI algorithm identifies most effective drugs for liver cancer
1st November 2021
Researchers from Barts Cancer Institute at Queen Mary University of London and King’s College Hospital have shown that a new computer-based algorithm can rank drugs used to treat primary liver cancer, based on their efficacy in reducing cancer cell growth.
Read more
Mapping the emergence of treatment resistance in leukaemia
28th September 2021
Research led by Barts Cancer Institute, Queen Mary University of London, has identified a new role for a group of cells called adipocytes in contributing to treatment resistance in a type of leukaemia. Published in Nature Communications, the findings broaden the understanding of resistance pathways in blood cancer cells, which is critical for developing novel treatment strategies to improve outcomes for people with leukaemia.
Read more
Dissecting complex biological pathways with machine learning
19th July 2021
We spoke with Group Leader Dr Jun Wang and Postdoctoral Researcher Dr Anthony Anene from Barts Cancer Institute’s Centre for Cancer Genomics & Computational Biology about their most recent publication. Published in Patterns, the paper describes the development of a machine-learning tool called ACSNI that can be used to predict tissue-specific pathway components from large biological datasets.
Read more
Immune cells assemble – boosting the effects of chemotherapy in pancreatic cancer
9th July 2021
A new study from Barts Cancer Institute, Queen Mary University of London, has demonstrated that immune cells can be stimulated to assemble into special structures within pancreatic cancer such that, at least in a pre-clinical model, researchers can demonstrate an improvement in the efficacy of chemotherapy.
Read more
Study identifies biomarker that could help to diagnose pancreatic cancer
29th June 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that could be used to aid in the diagnosis of pancreatic cancer. Findings from the new study suggest that a protein called pentraxin 3 may be a specific diagnostic biomarker – or biological measure – for pancreatic cancer, with the ability to differentiate pancreatic cancer from other non-cancerous conditions of the pancreas.
Read more
Study suggests blood test could guide precision treatment in bladder cancer
16th June 2021
A blood test that can detect tiny amounts of circulating cancer DNA may be able to identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery, according to a clinical study led by Professor Tom Powles from Barts Cancer Institute at Queen Mary University of London and Barts Health NHS Trust. The findings from the study, published today in Nature, may change our understanding of cancer care following surgery.
Read more